← Leaderboards
Susan Abushakra
Alzheon, Inc.
$51,190,244
Attributed
$51,190,244
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $15M · FY2020–24$20M$15M$10M$5M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$51,190,244 · 1
By mechanism
R01$51,190,244 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposBiological MarkersGenotypeS DiseaseRandomizedPhase 3 StudyOralNerve DegenerationPhase Iii TrialSafetyClinical ResearchSmall MoleculePlacebosBrainAmyloidDouble-Blind MethodMagnetic Resonance ImagingAlzheimerâS Disease BiomarkerAutomobile DrivingAducanumabAtrophicCharacteristicsApolipoprotein E-4Cerebral Atrophy
Grant awards (7)
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study$2,265,244
R01 · FY2024 · AG · contact PI
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study$6,500,000
R01 · FY2023 · AG · contact PI
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study$425,000
R01 · FY2023 · AG · contact PI
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study$11,000,000
R01 · FY2022 · AG · contact PI
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study - COVID supplement$3,500,000
R01 · FY2022 · AG · contact PI
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study$12,500,000
R01 · FY2021 · AG · contact PI
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study$15,000,000
R01 · FY2020 · AG · contact PI